Top Markets
#1 ICON ICON +156.44%
#2 ZetaChain ZetaChain +47.92%
#3 Four Four +39.72%
#4 Phala Phala +34.53%
#5 Chia Chia +33.77%
#6 Mubarak Mubarak +32.15%
#7 Nano Nano +27.88%
#8 SODAX SODAX +26.10%
#9 Bitway Bitway +24.95%
#10 PumpMeme PumpMeme +23.83%
Coin of the day
ICON ICON
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Zoetis Inc. Zoetis Inc.

Zoetis Inc.

ZTS
Classement en actions #827
Zoetis Inc. stands as a global leader in animal health, focusing on the... Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
Prix de l'action
$71.46
Capitalisation boursière
$29.96B
Changement (1 jour)
-0.04%
Changement (1 an)
-51.01%
Pays
US
Échange Zoetis Inc. (ZTS)

Catégorie

Healthcare
Revenus pour Zoetis Inc. (ZTS)
Revenus en Jun 2026 TTM : $9.52B
Selon les derniers rapports financiers de Zoetis Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $9.52B. En 2024, l'entreprise a réalisé un chiffre d'affaires de $9.26B une augmentation par rapport à le chiffre d'affaires de l'année 2023, qui était de $8.54B. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Zoetis Inc. de 2009 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
2026 (TTM) $9.52B 0.53%
2025 $9.47B 2.28%
2024 $9.26B 8.33%
2023 $8.54B 5.74%
2022 $8.08B 3.91%
2021 $7.78B 16.49%
2020 $6.68B 6.63%
2019 $6.26B 7.47%
2018 $5.83B 9.76%
2017 $5.31B 8.57%
2016 $4.89B 2.58%
2015 $4.77B -0.42%
2014 $4.79B 4.91%
2013 $4.56B 5.19%
2012 $4.34B 2.43%
2011 $4.23B 18.17%
2010 $3.58B 29.78%
2009 $2.76B 0.00%
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 $79.67B 737.09%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 $97.93B 928.99%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 $64.39B 576.54%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 $77.52B 714.53%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 $66.40B 597.70%
US